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ABSTRACT
ENGINEERING SPORES TO DISPLAY G PROTEIN-COUPLED RECEPTORS
FOR DIRECTED EVOLUTION
by
Alyssa Misoo Kim
All human cells are surrounded by a plasma membrane made from a phospholipid
bilayer, which is responsible for maintaining a biologically active species, while stopping
entry of deleterious substances from the outside. G protein-coupled receptors (GPCRs)
are the membrane proteins, which transmit signals across the cell membrane. GPCRs are
involved in almost every physiological process, and irregular control leads to
pathological conditions. Therefore, they are major drug targets. Crystal structure
determination is required to understand the molecular details of activation/deactivation.
However, GPCRs are difficult to crystallize because of stability issues. An efficient
protein engineering system needs to be developed. The goal is to design and create a
system to display a heterologous protein on the Bacillus subtilis spore coat. Human
parathyroid hormone receptor (huPTH1R) is used as a model system. HuPTH1R is a
GPCR, which is vital in regulating calcium and phosphate levels in the blood.
Molecular biology is used to create the plasmid pDG1730 huPTH1R-CotC that
fused huPTH1R to a spore coat protein, CotC. The plasmid is transformed into B. subtilis,
and huPTH1R is successfully integrated into B. subtilis genome via recombination. This
work represents the first system for GPCR display on the spore coat. Spore display
overcomes many of the hurdles found in “traditional” protein display systems. Finally,
this system can be used as a general method for engineering and optimizing membrane
proteins by directed evolution.
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CHAPTER 1
INTRODUCTION

1.1 G Protein-Coupled Receptors
G protein-coupled receptors (GPCRs) are integral membrane proteins characterized by
seven transmembrane helices (TM) connected by three extracellular loops (ECLs) and
three intracellular loops (ICLs) (1, 2) (Figure. 1.1).
NH3+

−

OOC

Figure 1.1 General structure of G protein-coupled receptors embedded in a lipid bilayer.
They are the largest family of membrane proteins in the human genome and
function as the receptors for hormones, neurotransmitters, protons, ions, light, odors and
gustative molecules

(2)

. Thus, they are essential for communication between internal and

external environments of cells. For example, the human β2 adrenergic receptor binds to
adrenalin and noradrenalin on the exterior of the cell, and it leads to activate stimulation
and regulation of the sympathetic nervous system.
GPCRs are involved in almost every physiological process. Hence, irregular
control leads to pathological conditions, which include cancer, cardiovascular, metabolic,
central nervous system and infectious diseases
1

(1)

. As a result, GPCRs are major human

drug targets. There are approximately 80 GPCR-targeting drugs in the current
pharmaceutical market with annual sales reaching up to $50 billion, and they make
approximately 30-50% of the drug targets

(1)

. Notable examples are Eli Lilly’s Zyprexa

(schizophrenia), Schering-Plough’s Clarinex (hay fever and allergy symptoms),
GlaxoSmithKline’s Zantac (gastroesophageal reflux disease), and Novartis’s Zelnorm
(irritable bowel syndrome). Therefore, crystal structure determination would provide
molecular details of activation and deactivation, which would have an enormous impact
in drug discovery.
GPCRs are divided into five families based on their sequence and structural
similarity: rhodopsin (Class A or Family 1), secretin/adhesion (Class B or Family 2),
glutamate (Class C or Family 3), Frizzled and Taste2

(1-3)

. The rhodopsin family is the

largest and most diverse family among these families. There are four subfamilies in this
diverse family: α, β, γ, δ. The α subfamily receptors activate the protons in retinal to
detect

the

light.

The

β

subfamily

receptors,

which

include

endothelin,

gonadotropin-releasing hormone and oxytocin receptor ligands, bind to peptides. The γ
subfamily consists of peptides or lipid-like receptors. Examples include somatostatin
receptor 2 and 5, angiotensin receptor 1, and chemokine receptors, which are drug targets
in this group. The δ subfamily is responsible for olfactory. The secretin family receptors
bind peptide hormones like calcitonin, glucagon and parathyroid hormone. These
hormones are used to regulate hypercalcaemia, hypoglycaemia and osteoporosis. In the
glutamate family, there are four kinds of receptors that include metabotropic glutamate,
GABAB, sweet and umami taste, and calcium sensing. These three main families can be
easily identified according by sequences comparison. Frizzled family consists of frizzled

2

and smoothened receptors involved in embrogenesis. The frizzled receptors bind Wnt
glycoproteins, whereas smoothened receptors perform as the signaling unit. Last, Taste2
family consists of taste receptors including bitter sensing.

1.2 Crystal Structure and Problems
To date, there are only eight different crystal structures for GPCRs, which include
rhodopsin (4, 5), β2AR (6), β1AR (7), adenosine A2A receptor (ADORA2A) (8), histamine H1
(9)

, sphingosine 1-phosphate

(10)

, and CXCR4 chemokine receptor

(11)

. Despite huge

research efforts in GPCR crystallography, determination of GPCRs structure is difficult
due to the protein properties.
A protein needs to be functionally expressed, purified, and crystallized in order to
successfully solve the crystal structure. However, there are several problems to determine
the crystal structure of GPCRs. First, GPCR expression in native tissue is typically very
low

(12)

; therefore, GPCRs need a recombinant expression system. GPCRs can be

overexpress in prokaryotic system such as Escherichia coli. However, they are expressed
as insoluble inclusion bodies. As a result, they must be solubilized and refolded using
detergents and other chemical additives. Next, compared to soluble or cytoplasmic
proteins, membrane proteins are difficult to crystallize because they are found in a lipid
bilayer. This environment is difficult to mimic during the crystallization procedure. In the
early 1980s, detergent-based micelles were designed to solubilize membrane proteins. In
addition, bilayer vesicles, lipidic mesophase approaches, and lipid/detergent procedures
were used to assist crystallization. Finally, GPCRs typically have thermodynamic and
proteolytic protein stability problems

(12)

. As a result, there is a lack of secondary

structure due to flexible segments of the protein.
3

The first GPCR structure was bovine rhodopsin (Figure. 1.2). This crystal
structure has provided useful information for activation mechanism of GPCRs.
Rhodopsin was more suitable for structural studies than most of other GPCRs because it
can be obtained large quantities of functional protein from retinas, and they are thermally
stable compared to other GPCRs.

Figure 1.2 Structure of rhodopsin (PDB ID: 3PQR) (13).
In order to improve proteolytic stability, several protein engineering efforts have
been employed. Recently, crystal structures of the human β2 adrenocepter (β2AR) as a
receptor for adrenalin and noradrenalin have been determined. β2AR was the first
non-rhodopsin GPCR to be cloned and was one of the most extensively studied members.
Two different protein engineering strategies were utilized. First, β2AR was stabilized by
binding a stable antibody fragment (Fab5) to the unstructured cytoplasmic ends of TM5
and TM6, which is linked by the third intracellular loop (ICL3)

4

(14)

(Figure. 1.3). Next,

the unstructured ICL3 sequence from Q230 to S262 was replaced with structured protein,
T4 lysozyme (T4L)

(14)

(Figure. 1.4). In essence, a stable protein (antibody or lysozyme)

was associated with the unstable GPCRs to impact an overall stable structure. In addition,
β1AR and β2AR were further stabilized by addition of stabilizing ligands, amino acid
substitutions, adding lipids, and high salt concentrations.

TM6

Fab5
Heavy chain

TM5

Fab5
Light chain
Fab5

Figure 1.3 Structure of β2AR-Fab5 (PDB ID: 2R4R) (6, 14).

5

T4L

TM6

T4L

TM5

T4 Lysozyme

Figure 1.4 Structure of β2AR-T4 lysozyme fusion
2RH1(15) and T4 lysozyme: 206L(16)).

(14)

(PDB ID of β2AR-T4 lysozyme:

There are still no crystal structures for most of the rhodopsin family and other
GPCR families such as the gamma-aminobutyric acid (GABA) or the metabotropic
glutamate receptors (mGluRs) in family 3.

1.3 Directed Evolution
Darwinists believe the diversity found on Earth is due to evolution

(17)

. Evolution does

not go toward a specific objective. It moves by random changes and it alters the capacity
of an organism to reproduce under the present conditions. An adapted organism to the
current conditions may fair better or worst when the environment changes. Next,

6

evolution requires a bit of “sloppiness”. This allows an organism to adapt to unexpected
changes in the environment. Furthermore, evolution is based on the past. New structures
and metabolic functions are created from pre-existing elements. Finally, evolution does
not end, and does not go towards absolute complexity. We hold that human beings are at
the top of the evolutionary scheme. However, a quick scan of the diversity of organisms
shows that simpler ones have not been extinct or stopped evolving. The timescale of
months to years can occur for natural evolution. One example is the appearance of
antibiotic resistant bacteria and enzymes that degrade chemically synthesized compounds
(18, 19)

.
The products of evolution occur on many different levels. It is responsible for the

diversity of life. In addition, evolution can be seen all the way down to single molecules
such as proteins. For example, human ribonuclease and angiogenin share similar tertiary
structures (Figure. 1.5). However, they have completely different functions. Ribonuclease
is a digestive enzyme while angiogenin stimulates blood vessel growth.

7

(B)

(A)

(C)
Paralogs

Human ribonuclease
(digestive enzyme)

Angiogenin
(stimulates blood-vessel growth)

Figure 1.5 (A) Human ribonuclease (PDB ID: 5RSA) (20). (B) Angiogenin (PDB ID:
1B1I) (21). (C) Paralogs that perform different functions in one organism.
Protein engineering strategies can be roughly categorized as rational or
evolutionary. Rational design requires detailed information of the protein structure and
function. Guided by the structure, individual amino acids are chosen for substitution in
order to modify the function. This is usually done by site directed mutagenesis

(22)

. Site

directed mutagenesis is a molecular biology method. A specific nucleotide in the DNA is
mutated, which results in change in an amino acid. Some successes include increased
thermostability

(23-26)

, altered substrate specificity

(27)

, and introducing post translation

modification (28). The main disadvantage of rational design is the effect of the amino acid
substitution cannot be predicted accurately. This is because we are still very ignorant on

8

how the changes affect every aspect of the protein. For example, we may be able to
introduce a new function, such as altered substrate specificity. However, it is impossible
to forecast the cost that the substitution has on a different property, such as
thermostability. In conclusion, we need a huge amount of structural, mechanistic, and
dynamic knowledge for a successful rational design effort. This information is only
known for a small fraction of proteins.
On the other hand, directed evolution is a method that mimics the process of
natural evolution in order to create mutants with novel and desired properties. The
greatest advantage is that a detailed knowledge of structure or mechanism is not required.
Directed evolution experiment has iterative cycles (Figure. 1.6). First, a library of genes
up to 1015 members is generated by molecular biology techniques. Second, the DNA
library is introduced into a suitable host. Typically, a library has 104-109 variants of the
parent. Third, proteins from the library with improved functions are identified by
appropriate screening or selection methods. Finally, the genes are used as parents for the
next round of directed evolution. Through these repeated cycles, useful and desired
mutations can accumulate like the natural evolution process. To name a few examples,
directed evolution has been used to alter substrate specificity, increase thermal stability,
organic solvent resistance, and enantioselectivity (29-31).

9

Expression
vector

Library of variants
up to 1015

Repeat
Parent protein
up to 101

Screening

104~10 9 variants
of the parent

YES
Evolved protein

NO

Figure 1.6 Basic steps of a directed evolution experiment. First, a library of genes is
created. The library of variants is up to 1015. Next, the library is cloned in an expression
vector and transformed in a host cell. The desired proteins are screened or selected from
the library. Finally, the improved proteins are used as parents for next round of evolution.
(PDB ID: 3PQR) (13)
There are several techniques used to create libraries. As an example, the most
common and successful methods are random mutagenesis, cassette mutagenesis, and in
vitro gene recombination (32).

10

1.4 Protein Display
In nature, proteins localized on the cell surface are important to function. For example,
they perform fundamental biological functions, including transportation such as
importing and exporting molecules, adhesion molecules and receptors, communication
between cells, signal transduction, and others

(33)

. Now, molecular biology has made it

possible to use these cell surface proteins for biotechnological application. For example,
microbial cell-surface display can be used to express a heterologous protein of interest as
a fusion with various anchoring motifs as carrier proteins. Applications include peptide
library screening

(34-36)

targeted therapies

, directed evolution of proteins

(36-38)

, biocatalyst

(36, 39)

(34, 35)

, bioadsorption

, vaccines development and

(36)

, mutation detection

(36)

,

biosensors (36), and bioremediation (34).
“Traditional” microorganisms used for protein display are phage
(33)

, and yeast

(34, 41)

(40)

, prokaryotes

. Protein display has several advantages when compared to libraries

expressed in the cytoplasm (Figure. 1.7). For libraries expressed in the cytoplasm, a
microtiter plate procedure may be needed to assay protein function. In a typical round of
evolution, up to 103-104 protein variants can be conveniently assayed. Cells are usually
arrayed in microtiter plates and they must be lysed to gain access to the protein. In this
step, the genotype/phenotype connection is disconnected. Next, the cell debris may be
required to be separated from the lysate. This step oftentimes necessitates multiple
centrifugation and pipetting steps, which needs automated robotic systems. Furthermore,
the lysate is a complex solution containing the target protein and the contents of the
cytoplasm, which includes endogenous proteins, nucleic acids, etc.

11

(B)

(A)

Figure 1.7 (A) Proteins (Blue) which are expressed inside the host cell. (B) Proteins
(Blue) which are displayed outside the host cell.
Protein display can overcome the obstacles presented above. First, the protein is
freely accessible and assayed easily. Next, multiple liquid handling steps are not
necessary because the cells are not lysed. Furthermore, the environment for screening
such as pH, buffer composition, and ionic strength can be easily controlled. Finally, the
genotype/phenotype remains intact.
A directed evolution strategy begins with determination of a suitable surface
display platform (phage, prokaryote or yeast), based on characteristics of the protein.
Gene libraries of the protein are created by random mutagenesis and/or recombination.
Cloned genes are inserted into plasmid. They are transformed into a host and induced.
Each cell has an individual member of the library on the cell surface, and screened for
function. Next, the cells are cultured, the gene is isolated, and another round of evolution
can be done (Figure. 1.8).

12

solid support

solid support

solid support

Figure 1.8 Protein screening of mutant libraries displayed the cell surface.

1.4.1 Phage Display
Bacteriophage is a virus that infects bacteria. Filamentous phage display was the first
system, which was developed by George P. Smith, and it remains the most common. A
peptide of interest can be fused with the pIII protein (Figure. 1.9)
(39, 44)

, and λ phage

antibodies

(47, 48)

(39, 44, 46)

(42, 43)

. T4

(39, 44, 45)

, T7

have also been used. Phage display has been used engineer

, discovery drug-like molecules

(49)

, and molecular biomimetics

addition, they have been used for the protein engineering (51, 52).
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(50)

. In

pIII gene

pIII gene

Foreign gene

pIII protein

Foreign gene

pIII protein
Foreign protein

Figure 1.9 Phage display. A foreign protein of interest is fused with the pIII protein.
An advantage of phage display is that it is easy to perform and inexpensive. A
library size of 1010 can be screened in a single day. Usually, three to five cycles are
enough to generate peptide sequences with high binding efficiency. However, the size of
the foreign protein to be displayed on the surface of phage is rather limited.

1.4.2 Microbial Cell Surface Display
Functional enzymes, peptides libraries, and antibody fragments have been displayed on
the cell surfaces of bacteria

(34)

. There are two microbial cell surface display systems,

gram-negative and positive. First, the architecture of gram-negative bacteria membrane
includes an inner membrane and outer membrane, and sandwiched between the two is a
peptidoglycan structure. Outer membrane proteins have been used as carriers to display
foreign proteins on the surface (Figure. 1.10). Foreign genes can be fused to outer
membrane proteins such as OmpA and the OmpC, PhoE, LamB, FhuA, and BtuB (33, 53).

14

Outer membrane
Outer membrane protein

Peptidoglycan layer

Passenger protein
Cytosol
Inner membrane

Figure 1.10 Gram-negative bacteria cell surface display.
Secondly,

gram-positive

bacteria

such

as

Staphylococcus

xylosus

or

Staphylococcus carnosus have been used. They have a thicker cell wall and lack the outer
membrane (Figure. 1.11). They are more suitable to apply for cell catalysts and
adsorbents because of cell wall rigidity. Bacillus and Staphylococcus strains have been
commonly used.
Cell wall
Peptidoglycan
Passenger protein
Cytosol

Figure 1.11 Gram-positive bacteria cell surface display.
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Library sizes of 109-1011 can be obtained and screened. On the other hand, a
major concern is a protein folding issue (vide infra). In addition, E. coli does not have the
machinery capable of post-translational modifications, such as glycosylation, necessary
for functional expression of eukaryotic proteins.

1.4.3 Yeast Surface Display
Yeast display has also been used to improve affinity, specificity, expression, stability, and
catalytic activity for various foreign proteins

(54)

. The Aga1-Aga2 protein complex in

Saccharomyces cerevisiae has been used as anchors for protein display (Figure. 1.12).
These proteins are covalently connected to the cell wall

(41, 55)

. This display system has

been utilized for presentation of various proteins such as green fluorescent protein (GFP),
blue fluorescent protein (BFP), the hepatitis B virus antigen, and glucoamylase (56, 57).
H2N

Aga2

COOH
Surface displayed protein

Aga1
Yeast

Figure 1.12 Yeast surface display. The surface displayed protein of interest is fused by
its N-terminus to the C-terminus of Aga2 protein.
There are several advantages in yeast surface display for protein engineering.
Yeast can display large proteins up to 500 amino acids; whereas, a filamentous phage is
limited to small peptides. Yeast can perform post-translational modifications. Hence, they
are suitable for functional expression of eukaryotic proteins that need glycosylation for
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protein folding (54). On the other hand, a potential drawback of yeast surface display is the
smaller library size of 106-107, which is due to low transformation efficiency.
Furthermore, protein folding can be a problem (vide infra).

1.4.4 Ribosome Display
Ribosome display is cell free evolution technology to create proteins libraries (Figure.
1.13). The DNA library contains all the signals for transcription and translation. In
ribosome display, the translated protein remains connected to the ribosome because there
is no stop codon. As a result, a ternary complex of mRNA, ribosome, and protein produce
is used for selection (58).
DNA
Step 1

mRNA
Step 2

Step 5

PCR
Step 3

Step 4

mRNA

Figure 1.13 Ribosome display for screening for protein libraries. Step 1. DNA library
contains the T7 promoter, ribosome binding site, and stem-loops. Step 2. The mRNA is
translated. Translation is stopped by cooling to 4°C, and the protein is screened for
function. Step 3. Libraries are screened. Step 4. The mRNA is isolated. Step 5. The
mRNA is transcribed to cDNA with reverse transcriptase.
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Ribosome display has been used to screen antibody libraries
proteins with increased stability

(61)

(59)

, peptides

(60)

,

. An advantage of ribosome display is that large

libraries up to 1012-1013 can be screened. However, there are some issues, which include
protein misfolding, instability mRNA-ribosome-protein complex, and disulfide bonds
formation (62).

1.4.5 mRNA Display
Another in vitro evolution technology is mRNA display for protein and peptide selections
(Figure. 1.14).
Like ribosome display, mRNA display produces libraries up to 1012-1013. As a
result, rare sequences can be identified. The mRNA display system has advantage over
the ribosome display. The covalent mRNA-protein complex linked by puromycin has
resistance to harsh environments. A shortcoming of mRNA display is purification of the
protein-puromycin-DNA-mRNA from the ribosome (62).
The mRNA display technique has been used to create libraries of heavy domains
and single-chain antibodies as well as select linear and constrained peptides
Furthermore, selections in mRNA display system can identify polypeptide substrates
and cellular polypeptides (64) for signaling proteins and small molecular drugs.
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(62)

.

(63)

DNA

Transcription
mRNA

Ligation to puromycin

Translation

Peptidyl transferase
reaction

Purification

PCR

Reverse transcription

Affinity selection

Release of DNA by
RNA hydrolysis
ssDNA

Figure 1.14 mRNA display. Step 1. The DNA library is transcribed to mRNA. Step 2.
Puromycin is linked to the mRNA. Step 3. Translation is done in vitro. Step 4.
Translation is stopped at the linker region. Puromycin binds to the ribosome. Step 5.
Protein is transferred to puromycin. Step 6. mRNA is transcribed. Step 7. Selection for
desired properties. Step 8. Isolate DNA. Step 9. Synthesize double stranded DNA by
PCR.
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1.4.6 Spore Display
Protein display methods have revolutionized protein engineering in academic and
industrial settings. However, these technologies suffer several limitations, which have
been discussed above. More importantly, there are two significant issues; protein folding
and cell viability. Initially, protein must be folded properly for function. In E. coli display,
the protein is expressed in cytoplasm, which has a reducing environment. This hinders
correct disulfide bond formation. In addition, the unfolded peptide must cross the inner
membrane, peptidoglycan layer, and the outer membrane. Again, protein folding is a
concern. Next, screening proteins for extreme properties, such as organic solvent
resistance or thermal stability, will destroy the cell. This will also occur when assaying
with toxic substrates. As a result, the microorganism cannot be cultured, and the
genotype/phenotype connection will be lost.
Spore display may solve protein folding and cell viability issues. Protein folding
concerns may be bypassed due to the natural sporulation process (65) (Figure. 1.15). First,
the vegetative cell divides into two compartments, the mother cell and forespore. The
mother cell nurtures the formation of the spore. Spore coat proteins are synthesized in the
mother cell and they are deposited to form the coat. In short, proteins found on the
surface of the spore do not have to cross membranes. In addition, the mother cell contains
ATP-dependent chaperone protein to assist in protein folding (36).
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Vegetative cell
Mother cell

Forespore

Spore coat

Figure 1.15 Sporulation in Bacillus Subtilis.
Second, they are capable of enduring harsh physical and chemical conditions such
as heat, radiation, ultraviolet, desiccation, and oxidizers. Spores remain viable under
these conditions, while microorganism such as yeast and E. coli cannot. As a result,
screening protein with extreme properties can be achieved, and the genotype/phenotype
connection remains intact.
Spore display may also have additional advantages. In general, immobilized
proteins

(66)

have some economical and technological benefits. They are separated easily

from the reaction mixture, and the protein stability is increased. For protein
immobilization, it is typically expressed, purified, and attached to an inert material.
However, proteins are “pre-immobilized” during the sporulation process.
Surface display on B. subtilis has been used in biotechnological and
pharmaceutical applications

(36)

such as vaccines, biosensors, whole cell catalysts, and

bioabsorbants for toxic substances

(66)

. Most recently, spores have been shown to a
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suitable platform for directed evolution (67). B. subtilis is convenient organism for protein
display. The genome is known and they can be easily manipulated with molecular
biology techniques. Furthermore, spores can be easily produced in large quantities. Lastly,
they are safe to use and have been developed as additives for foods and drugs.
Spore Display of G-Protein Coupled Receptors: Human Parathyroid Hormone
Receptor 1 (huPTH1R)
As mentioned above, obtaining high-resolution crystal structures is a major obstacle
towards understanding the molecular mechanisms of GPCR constitutive activity and
activation. One significant challenge is acquiring a sufficient amount of protein to
crystallize because most GPCRs are expressed at low levels in native tissue. Hence, a
suitable recombinant expression system must be developed to produce correctly folded
protein, and insect and COS-1 mammalian cells have been used for this purpose
coli has been also used to generate GPCRs

(68)

(68)

. E.

. However, the proteins are expressed as

inclusion bodies and they require detergents and other chemical additives for
solubilization and refolding.
Spore display offers the opportunity to employ directed evolution methods to
stabilize GPCRs. This evolutionary approach would complement other stability methods,
such as antibodies binding

(6, 14)

, T4 lysozyme grafting

(14, 15)

, and other protein

engineering efforts were also used. One notable example was the evolution of GPCRs for
higher expression and stability, which was achieved in two steps

(69)

. First, a library of

GPCRs was expressed in the inner membrane of E. coli, and GPCRs with increased
expression level were sorted with Fluorescence-Activated Cell Sorting, FACS. Second,
the improved variants were screened for thermal stability using microtiter plates. The
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clones were expressed and tagged with biotin, and then they were partially purified using
streptavidin coated magnetic beads. Finally, they were assayed for enhanced thermal
stability.
Spore display of GPCRs may be a general tool for engineering these proteins by
overcoming several concerns. First, spore display results in “purified” protein on the
spore surface because each spore will contain a unique member of the library. Next, the
displayed GPCRs are expected to be unfolded and they need to be solubilized and
refolded. As mentioned above, this step requires detergents and other chemical additives.
Spores can endure extreme environments and they still remain viable. Hence, spores are
not affected during the refolding process. On the other hand, the refolding conditions are
not compatible for the more established protein display formats, such as E. coli and yeast,
because the cell wall may rupture. This would result losing in the genotype/phenotype
connection. Finally, only the GPCRs that can be expressed and assayed will be displayed.
For example, GPCRs with rare codon usage in B. subtilis may be removed during the
library creation and screening procedure. In short, spore display can be a general tool to
engineer proteins.
The goal of this project is to design and create a system for spore display. The
molecular biology will be performed in order to fuse a GPCR, human parathyroid
hormone receptor 1 (huPTH1R), to the spore coat protein, CotC. HuPTH1R is vital in
regulating calcium and phosphate levels in the blood (70). Defects in huPTH1R can result
in dwarfism, bone tumors, and failure of tooth eruption.
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CHAPTER 2
DESIGNING A SYSTEM FOR DISPLAYING HUMAN PARATHYROID
HORMONE RECEPTOR 1 ON THE SPORE COAT OF BACILLUS SUBTILIS
In this chapter, the design is described for the construction of a system to display
G-protein coupled receptors on spore coat of Bacillus subtilis. More specifically, the
cloning design and molecular biology will be outlined.

2.1 Materials
Analytical regent grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO),
BD (Franklin Lakes, NJ), Research Products International Corp. (Mount Prospect, IL),
and Invitrogen (Carlsbad, CA). Restriction enzymes were purchased from Invitrogen
(Carlsbad, CA) and New England Biolabs (Ipswich, MA). T4 DNA ligase and Taq DNA
polymerase were from Invitrogen (Carlsbad, CA), and PfuUltra HF DNA polymerase
was from Ailgent technologies (Santa Clara, CA). Primers were procured from Eurofins
MWG Operon (Huntsville, AL). QuikChange Site-Directed Mutagenesis Kit was
purchased from Ailgent technologies (Santa Clara, CA). QIAprep spin miniprep kit,
QIAquick PCR Purification Kit, and QIAquick gel extraction kit were purchased from
Qiagen (Valencia, CA). DNA sequencing was performed at Molecular Resource Facility
in University of Medicine and Dentistry of New Jersey (Newark, NJ).
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2.2 Methods

2.2.1 Remove XhoI Restriction Site at Position 7049 Base Pair for Ease of Cloning
The PCR reaction mixture consist of 5µl of 10X reaction buffer, 5 to 50ng template,
pDG1730 GFP-CotC, 125ng of pDG1730 XhoI forward (pDG1730 XhoI-F:
5'-GGAAGTATCCAGCTCCAGGTCGGGCCGCG-3') and pDG1730 XhoI reverse
primer

(pDG1730

XhoI-R:

5'-CGCGGCCCGACCTGGAGCTGGATACTTCC-3'),

respectively, 1µl of dNTP mix and ddH2O to a final volume of 50µl. Then, 1µl pfuTurbo
DNA polymerase (2.5U/µl) was added. The PCR consisted of 1 cycle at 95°C for 30
seconds and 12 cycles at 95°C for 30 seconds, 55°C for 1 minute and 68°C for 4 minutes.
After the PCR reaction, the product were directly digested with 1µl of the DpnI
restriction enzyme (10U/µl), and incubated at 37°C for an hour. After digestion, it was
transformed into XL1-Blue supercompetent cells by heat shock. The transformed cells
were plated on the Luria–Bertani (LB) plate containing ampicillin (50µg/mL) and
incubated at 37°C overnight. The mutated plasmid was isolated using QIAprep spin
miniprep kit, and both original and mutated plasmids were digested with XhoI and EcoRI
to check and compare the results. The mutation was verified by agarose gel
electrophoresis.

2.2.2 Amplification of Human Parathyroid Hormone Receptor 1
Human parathyroid hormone receptor 1 (huPTH1R) was amplified from the plasmid
pET15b huPTH1R (Aline Desmyster, Architecture et Fonction des Macromolécules
Biologiques, UMR 6098, CNRS, and Universités of Marseille, F-13288 Marseille Cedex
09, France) (68). The reaction mixture contain 5µl of 10X PfuUltra HF reaction buffer, 1µl
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of dNTP mix, 100ng/µl of pET15b – huPTH1R template, 100ng/µl each of huPTH1R –
HindIII-F

(5'-GGCAAGCTTACATAAGGAGGAACTACTATGGGCAGCAGCCATC

ATC-3') and huPTH1R – XhoI-R (5'-CGGCTCGAGCATGACTGTCTCCCACTCTTCC
-3'), 1µl of PfuUltra HF DNA polymerase (2.5U/µl), and up to 50µl with sterile ddH2O.
The PCR consisted of 1 cycle at 95°C for 2 minutes, 30 cycles at 95°C for 30 seconds,
65°C for 30 seconds and 72°C for 4 minutes, and then 1 cycle 72°C for 10 minutes. The
PCR amplification products were purified using QIAquick PCR Purification Kit and
analyzed on a 1% (w/v) agarose gel.

2.2.3 Construction of pDG1730 HuPTH1R-CotC
2.2.3.1 Digestion of pDG1730 GFP-CotC and HuPTH1R PCR Fragments.

The

reaction mixture contained HindIII, 10X buffer, each of pDG1730 GFP-CotC or
huPTH1R PCR fragments from above, and to a final volume 50µl. Both mixtures were
incubated at 37°C for 3 hours. The digested pDG1730 GFP-CotC and huPTH1R
fragments were purified using QIAquick PCR Purification, and then second digestion
with XhoI was performed. The reaction mixture included XhoI, 10X buffer, digested
pDG1730 GFP-CotC and huPTH1R PCR fragments, respectively, and up to 50µl with
sterile ddH2O. Incubation conditions were at 37°C for 3 hours again. Finally, the products
were purified using QIAquick gel extraction kit to select desired size of fragments.
2.2.3.2 Ligation of HuPTH1R and pDG1730 CotC.

Purified huPTH1R (insert)

and pDG1730 (vector) were ligated (Figure. 2.1 A). The 20µl ligation reaction contained
4µl of 5X ligase reaction buffer, insert and vector (1:1, 3:1, 6:1, and 9:1), and 0.1 unit of

26

T4 DNA ligase. The ligation was performed at 25°C for 1 hour. The final plasmid
construct, pDG1730 huPTH1R-CotC (Figure. 2.1 B), was created.
BamHI
HindIII

BamHI

EcoRI

bla

amyE’

bla

amyE’

spc
XhoI

HindIII

PCotC
huPTH1R

pDG1730

pDG1730 huPTH1R-CotC
CotC

erm

‘amyE

spc

erm

XhoI
EcoRI

‘amyE

(A)

(B)

Figure 2.1 Plasmid maps. (A) pDG1730. (B) pDG1730 huPTH1R-CotC. Genes; amyE’:
encodes front of α-amylase; ‘amyE: encodes back of α-amylase; spc: encodes
spectinomycin adenyltransferase (spectinomycin resistance); bla: encodes β-lactamase
(ampicillin resistance); erm: encodes rRNA adenine N-6-methyltransferase
(erythromycin resistance). BamHI, HindIII, EcoRI and XhoI are the restriction sites.

2.2.3.3 Transformation of pDG1730 huPTH1R-CotC.

The

ligated

plasmid

was

transformed into XL10-gold ultracompetent cells by electroporation. The transformed
cells were spread on the LB agar plate containing ampicillin (50µg/mL), and incubated at
37°C overnight. The plasmid was isolated using QIAprep spin miniprep kit. The insert
was verified with DNA sequencing (UMDNJ).
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Figure 2.2 Cloning strategies.
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XhoI
EcoRI

EcoRI

2.2.4 Bacillus subtilis Transformation
The plasmid pDG1730 huPTH1R-CotC was linearized by digestion with SpeI at 37°C for
3 hours and used to transform competent cells of the CotC knockout B. subtilis strain
(Figure. 2.3). The B. subtilis cells were plated on the LB agar plate containing
spectinomycin (100µg/mL) and chloramphenicol (5µg/mL), and then they were incubated
at 37°C overnight. The plasmid pDG1730 huPTH1R-CotC was integrated into the
non-essential amyE gene by double crossover recombination. This integration was
verified using PCR and the primers used were huPTH1R – HindIII-F and huPTH1R –
XhoI-R. The reaction and cycling condition was the same as for the amplification of
huPTH1R. Next, wild-type B. subtilis and B. subtilis transformed with pDG1730
huPTH1R-CotC were spread on the LB agar plate containing spectinomycin (100µg/mL)
and analyzed by growth on the plate with appropriate antibiotics. Finally, genomic DNA
was isolated, and the gene was sequenced (UMDNJ).
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Figure 2.3 Integration of pDG1730 huPTH1R-CotC into Bacillus subtilis genome.
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CHAPTER 3
RESULTS AND DISCUSSION

3.1 Remove XhoI Restriction Site at Position 7049 Base Pair for Ease of Cloning
The plasmid pDG1730 GFP-CotC (Patrick Eichenberger, Department of Biology, New
York University) contains two XhoI restriction sites (CTCGAG). A guanine to cytosine
point mutation was performed at position 7049 using QuikChange Site-Directed
Mutagenesis. It was necessary to have only one XhoI restriction site for ease of cloning.
To verify the result of removing XhoI restriction site, the plasmid pDG1730 GFP-CotC
and the mutated plasmid was digested with XhoI and EcoRI (Figure. 3.1).
The pDG1730 GFP-CotC and the mutated plasmids were digested with EcoRI. It
is expected to generate one linear fragment, 8903bp (Figure. 3.1, Lanes 2 and 3) because
there is only one restriction site. On the other hand, the plasmid pDG1730 GFP-CotC was
digested with XhoI. It is expected to result in two fragments, 5308 bp and 3595 bp
(Figure. 3.1, Lanes 4). The mutated plasmid has only one XhoI restriction site, and the
digestion is expected to have a single 8903 bp fragment (Figure. 3.1, Lanes 5).
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1

2
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4

5

12000bp
9000bp
5000bp

Figure 3.1 Analysis of mutation of XhoI restriction site by gel electrophoresis. Lane 1:
1kb DNA plus ladder, Lane 2: EcoRI digestion of pDG1730 GFP-CotC original plasmid,
Lane 3: EcoRI digestion of QuikChange site-directed mutation of pDG1730 GFP-CotC
plasmid, Land 4: XhoI digestion of pDG1730 GFP-CotC original plasmid, Lane 5: XhoI
digestion of QuikChange site-directed mutation of pDG1730 GFP-CotC plasmid.

3.2 Amplification of Human Parathyroid Hormone Receptor 1
The huPTH1R gene was successfully amplified from the plasmid pET15b huPTH1R
(Aline Desmyster, Architecture et Fonction des Macromolécules Biologiques, UMR
6098, CNRS, and Universités of Marseille, F-13288 Marseille Cedex 09, France) (68) with
huPTH1R – HindIII-F and huPTH1R – XhoI-R, which were the forward and reverse
primers, respectively. The forward primer incorporated a HindIII restriction site at the 5’
end, while the reverse primer integrated an XhoI restriction site at the 3’ end. The PCR

32

reaction was purified using QIAquick gel extraction kit, and PCR products were analyzed
on the 1% (w/v) agarose gel. The expected size of huPTH1R was 1806bp (Figure. 3.2,
Lane 3).
1

2

3

2000bp
1650bp

Figure 3.2 Analysis of huPTH1R gene by gel electrophoresis. Lane 1: 1kb DNA plus
ladder, Lane 2: pET15b huPTH1R original plasmid, Lane 3: huPTH1R PCR products.

3.3 Construction of pDG1730 HuPTH1R-CotC
The plasmid pDG1730 huPTH1R-CotC was constructed. First, the pDG1730 GFP-CotC
and huPTH1R PCR product were digested with HindIII and XhoI. This created sticky
ends in order to ligate the vector (digested pDG1730 GFP-CotC) and the insert (digested
huPTH1R PCR product). The digestions were analyzed by agarose gel electrophoresis.
The digested insert shows one band at 1806 bp (Figure. 3.3, Lane 3).
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1

2

3

2000bp
1650bp

Figure 3.3 Analysis of huPTH1R PCR fragments after XhoI digestion by gel
electrophoresis. Lane 1: 1kb DNA plus ladder, Lane 2: pET15b huPTH1R original
plasmid, Lane 3: huPTH1R PCR fragments.
The double digestion of pDG1730 GFP-CotC resulted in two bands. The band at
738bp corresponds to the coding region for GFP, and the band at 8165 bp was remaining
part of the plasmid pDG1730 CotC, which was used as the vector (Figure. 3.4, Lanes 2
and 3).
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GFP

650bp

Figure 3.4 Analysis of pDG1730 GFP-CotC after XhoI digestion by gel electrophoresis.
Lane 1: 1kb DNA plus ladder, Lanes 2 and 3: pDG1730 CotC and GFP, Lane 4:
pDG1730 GFP-CotC original plasmid.
The vector and insert were cut out and purified from the gel using a QIAquick gel
extraction kit. Separate ligation reactions were done with insert to vector ratio of 1:1, 3:1,
6:1, and 9:1. Then, the ligated plasmids were transformed into XL10-gold ultracompetent
cells by electroporation and plated on the LB agar plate containing ampicillin (50µg/mL).
Several colonies were selected, and plasmids were isolated using QIAprep spin miniprep
kit. Successful ligation was determined by PCR amplification of the insert, huPTH1R. A
clone was found in the 3:1 insert to vector reaction, which displayed an 1806 bp fragment
(Figure. 3.5, Lane 6). This plasmid was requested DNA sequencing (UMDNJ), and the
results verified presence of the insert (Appendix A).
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Figure 3.5 Analysis of huPTH1R after transformation by gel electrophoresis. Lane 1:
1kb DNA plus ladder, Lane 2: huPTH1R PCR products for positive control, Lane 3 ~ 6:
huPTH1R PCR products after transformation.

3.4 Bacillus subtilis Transformation
The plasmid pDG1730 huPTH1R-CotC was linearized with the restriction enzyme SpeI,
and it was transformed into competent cells of the CotC knockout B. subtilis strain. The
B. subtilis cells were spread on the LB agar plate containing spectinomycin (100µg/mL)
and chloramphenicol (5µg/mL). Several colonies were chosen, and the genomic DNA
was isolated. PCR was performed with the genomic DNA, and a product corresponding
with the correct size of huPTH1R PCR (1794 bp) was detected by agarose gel
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electrophoresis (Figure. 3.6, Lane 3). In addition, genomic DNA was isolated and
sequenced (UMDNJ) for the presence of the huPTH1R gene (Appendix B).
1

2

3

2000bp
1650bp

Figure 3.6
Analysis of recombination of pDG1730 huPTH1R CotC by gel
electrophoresis. Lane 1: 1kb DNA plus ladder, Lane 2: huPTH1R PCR products for
positive control, Lane 3: huPTH1R PCR products after B. subtilis transformation.
Next, integration of pDG1730 huPTH1R-CotC resulted in conferring antibiotic
resistance to spectinomycin resistance. Wild type of B. subtilis did not grow on the LB
agar plate containing spectinomycin (100µg/mL), while the transformed B. subtilis strain
did (Figure. 3.7).
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(A)

(B)

Figure 3.7 Growth characteristics of B. subtilis with LB agar plates containing
spectinomycin (100µg/mL). (A) Wild-type B. subtilis. (B) B. subtilis strain transformed
with pDG1730 huPTH1R-CotC.
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CHAPTER 4
CONCLUSION

In conclusion, integration of huPTH1R into B. subtilis was successfully done. First,
molecular biology was used to create the plasmid pDG1730 huPTH1R-CotC that fused a
GPCR (huPTH1R) to a spore coat protein (CotC). Next, pDG1730 huPTH1R-CotC was
transformed into B. subtilis display to integrate the GPCR into the genome. This work
represents the first system for GPCR display on the spore coat. Spore display overcomes
many of hurdles found in “typical” protein display systems. Furthermore, this system can
be used a general method for engineering and optimizing membrane proteins by directed
evolution. The next goals are to demonstrate proper GPCR display on the spore coat, and
then the protein will be evolved for stability.
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APPENDIX A
SEQUENCING ANALYSIS RESULTS

Figure A.1 to A.8 show DNA sequencing results of pDG1730 huPTH1R-CotC.
(A)

Figure A.1 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-F1 (5’-TATGCCGCGATTTCCAATGAGG-3’). Nucleotide 641 is the start of PCotC
and 3015 is end of CotC. This alignment represents 641 ~ 1500.
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(B)
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Figure A.1 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-F1. (Continued)
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(A)

Figure A.2 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-F2 (5’-GGCAAGCTTACATAAGGAGGAACTACTATGGGCAGCAGCCATCA
TC-3’). Nucleotide 641 is the start of PCotC and 3015 is end of CotC. This alignment
represents 1046 ~ 1900.
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(B)
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Figure A.2 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-F2. (Continued)
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(A)

Figure A.3 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-F3 (5’-CACAACAGGACGTGGGCCAACTACAG-3’). Nucleotide 641 is the start
of PCotC and 3015 is end of CotC. This alignment represents 1560 ~ 2400.
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(B)
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Figure A.3 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-F3. (Continued)
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(A)

Figure A.4 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-F4 (5’-GGCCACCAACTACTACTGGATTCTGG-3’). Nucleotide 641 is the start
of PCotC and 3015 is end of CotC. This alignment represents 1955 ~ 2700.
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(B)
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Figure A.4 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-F4. (Continued)
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(A)

Figure A.5 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-F5 (5’-GCAATGGCGAGGTACAAGCTGAGATC-3’). Nucleotide 641 is the start
of PCotC and 3015 is end of CotC. This alignment represents 2471 ~ 3015.
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(B)

53

Figure A.5 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-F5. (Continued)

54

(A)

Figure A.6 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-R2 (5’-CGGCTCGAGCATGACTGTCTCCCACTCTTCC-3’). Nucleotide 641 is
the start of PCotC and 3015 is end of CotC. This alignment represents 1892 ~ 2764.
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(B)

56

Figure A.6 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-R2. (Continued)

57

(A)

Figure A.7 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-R4 (5’-CCAGAATCCAGTAGTAGTTGGTGGCC-3’). Nucleotide 641 is the start
of PCotC and 3015 is end of CotC. This alignment represents 1034 ~ 1879.
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(B)

59

Figure A.7 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-R4. (Continued)

60

(A)

Figure A.8 DNA sequencing results of pDG1730 huPTH1R-CotC. (A) Top strand is the
DNA coding region from the promoter of CotC to CotC, PCotC-huPTH1R-CotC DNA.
The bottom strand represents the DNA sequencing results using the primer seq-huPTH1R
CotC-R5 (5’-GATCTCAGCTTGTACCTCGCCATTGC-3’). Nucleotide 641 is the start
of PCotC and 3015 is end of CotC. This alignment represents 1516 ~ 2380.
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(B)

62

Figure A.8 DNA sequencing results of pDG1730 huPTH1R-CotC. (B) DNA sequencing
traces were done with the primer seq-huPTH1R CotC-R5. (Continued)

63

APPENDIX B
SEQUENCING ANALYSIS RESULTS

Figure B.1 to B.8 show genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC.
(A)

Figure B.1
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-F1 (5’-TATGCCGCGATTTCC
AATGAGG -3’). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This
alignment represents 1 ~ 849.
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(B)

65

Figure B.1
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-F1. (Continued)

66

(A)

Figure B.2
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-F2 (5’-GGCAAGCTTACAT
AAGGAGGAACTACTATGGGCAGCAGCCATCATC-3’). Nucleotide 1 is the start of
PCotC and 2735 is end of CotC. This alignment represents 406 ~ 1375.
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(B)

68

Figure B.2
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-F2. (Continued)

69

(A)

Figure B.3
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-F3 (5’-CACAACAGGACGTG
GGCCAACTACAG-3’). Nucleotide 1 is the start of PCotC and 2375 is end of CotC. This
alignment represents 920 ~ 1802.
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(B)

71

Figure B.3
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-F3. (Continued)

72

(A)

Figure B.4
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-F4 (5’-GGCCACCAACTACTA
CTGGATTCTGG-3’). Nucleotide 1 is the start of PCotC and 2375 is end of CotC. This
alignment represents 1302 ~ 2087.
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(B)

74

Figure B.4
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-F4. (Continued)

75

(A)

Figure B.5
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-F5 (5’-GCAATGGCGAGGTA
CAAGCTGAGATC-3’). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This
alignment represents 1832 ~ 2735.
(B)

76

Figure B.5
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-F5. (Continued)

77

(A)

Figure B.6
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-R2 (5'-CGGCTCGAGCATGAC
TGTCTCCCACTCTTCC-3'). Nucleotide 1 is the start of PCotC and 2735 is end of CotC.
This alignment represents 1628 ~ 2124.
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(B)

Figure B.6
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-R2. (Continued)

79

(A)

Figure B.7
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-R4 (5'-CCAGAATCCAGTAGT
AGTTGGTGGCC-3'). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This
alignment represents 300 ~ 1239.
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(B)

81

Figure B.7
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-R4. (Continued)

82

(A)

Figure B.8
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (A) Top strand is the DNA coding region from the promoter of CotC to
CotC, PCotC-huPTH1R-CotC DNA. The bottom strand represents the genomic DNA
sequencing results using the primer seq-huPTH1R CotC-R5 (5'-GATCTCAGCTTGTAC
CTCGCCATTGC-3'). Nucleotide 1 is the start of PCotC and 2735 is end of CotC. This
alignment represents 809 ~ 1729.
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(B)

84

Figure B.8
Genomic DNA sequencing results of integration of pDG1730
huPTH1R-CotC. (B) Genomic DNA sequencing traces were done with the primer
seq-huPTH1R CotC-R5. (Continued)
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